About us
The Division of Cancer Studies at King's College London is part of one of the leading cancer research centres in Europe, the King's Health Partners' Integrated Cancer Centre.
Our multidisciplinary research portfolio maps onto and spans the entire cancer patient journey. By fostering a culture of innovation in cancer patient care through research excellence, we aim to break down traditional clinical and academic boundaries and draw together members of the Division and our associated major NHS partners to achieve a fully integrated cancer research pathway. This is reflected in the coordinated strategic planning that provides the foundations for our Integrated Cancer Centre.
The Centre's mission is to combine first class clinical care with groundbreaking research to bring direct benefits to patients and those further afield. Staff in the Division and associated NHS partner hospitals foster a culture of innovation in cancer patient care through multidisciplinary research excellence.
Research focuses on haemato-oncology, breast cancer biology, epidemiology, cancer cell biology and palliative care. The Division benefits from unique resources such as the Bio-Bank and the Thames Cancer Registry.
Research teams are developing alternative and individualised patient care options, including clinical trials and palliative care programmes designed to optimise quality of life, as well as rigorously quantifying benefits for patients.
Members of our distinguished team of academics have been recognised for their outstanding work in the field of Cancer research. Head of the Division, Professor Peter Parker was awarded a Fellowship of the Royal Society in 2006 and Professor Irene Higginson, Head of the Palliative Care, Policy & Rehabilitation, was awarded an OBE for services to medicine in the 2008 Queen’s birthday honours.
The Division is also committed to training future researchers and currently has 50 students studying for a PhD in the Division. We also run a number of post-graduate courses in Palliative Care and in September 2009 we launched the first year of our MRes in Translational Cancer Medicine.